Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic kidney disease (CKD). SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. Inflammatory responses play a prominent role in the pathophysiology of CKD as several structural and functional disorders of renal failure are strongly related to the overproduction of proinflammatory mediators. The present review discusses the anti‐inflammatory properties of SGLT2 inhibitors. The different molecular pathways through which SGLT2 inhibitors may affect inflammation in the kidneys are also commented upon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 1×
“…risk reductions in incident or worsening nephropathy (by 39%), doubling of serum creatinine (by 44%), and reduction in the potential for renal replacement (by 55%), thus highlighting the benefits of empagliflozin in the prevention or delay of kidney disease progression (Wanner et al., 2016).”
BackgroundHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · cited 1×
“Furthermore, empagliflozin was shown to decrease markers of oxidative stress in both the circulation and the aorta of diabetic mice (Oelze et al., 2014) as well as in the mitochondria of cardiac endothelial cells (Zhou et al., 2018).”
BackgroundVallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483 · cited 3×
“SGLT2 inhibitors normalize hyperglycemia, thus beneficially affecting renal hemodynamics (Fioretto, Zambon, Rossa- to, Busetto, & Vettor, 2016) and, subsequently, improving renal inflammation (Vallon et al., 2013).”
BackgroundRole of the renin–angiotensin system in vascular inflammation
Marchesi, C., Paradis, P., & Schiffrin, E. L. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.003 · Cited by 432
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281 · cited 2×
“Further- more, in animal studies, empagliflozin reduced the mRNA expression and circulating levels of MCP‐1, interleukin‐6 (IL‐6), and TNF‐α in aortic plaques and adipose tissue (Han et al., 2017), as well as nuclear factor κB (NF‐κB) and IL‐6 levels in renal tissues (Vallon et al., 2013).”
BackgroundXiao, L., Kirabo, A., Wu, J., Saleh, M. A., Zhu, L., Wang, F., Takahashi, T., Loperena, R., Foss, J. D., Mernaugh, R. L., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.306010 · Cited by 233 · cited 1×
“Innate immune system activation is a prominent marker of inflammation and oxidative stress (Xiao et al., 2015).”
BackgroundOjima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Poulsen, S. B., Fenton, R. A., & Rieg, T. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000152 · Cited by 164 · cited 2×
“However, in the case of SGLTs inhibition, the glucose reuptake mechanism is impaired and, consequently, a large proportion of the glucose in the filtrate is excreted in the urine (Poulsen et al., 2015).”
BackgroundTanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0457-8 · Cited by 140
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
Cited by
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
Metadata
- Authors
- Yaribeygi, H., Butler, A. E., Atkin, S. L., Katsiki, N., & Sahebkar, A.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-08-04
- Volume
- 234
- Issue
- 1
- Pages
- 223-230
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2886679183
- Cited by
- 148
- References
- 12
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.